Abstract CT090: DAREON™-7: A Phase 1, Open-Label, Dose Escalation and Expansion Cohort Trial of the Delta-Like Ligand (Dll3)-Targeting T-cell Engager BI 764532, Plus First-Line Platinum-Based Chemotherapy in Patients with DLL3-positive (+) Neuroendocrine Carcinomas
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined